Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

Optimal timing of G-CSF administration for effective autologous stem cell collection

Bone Marrow Transplantation volume 46, pages 806–812 (2011)Cite this article

Subjects

Abstract

The best time of G-CSF administration for PBPC collection remains to be defined. We aimed to identify optimal G-CSF administration timing for efficient autologous stem cell collection. A total of 262 lymphoma or multiple myeloma patients, who underwent PBPC collection from January 2000 to March 2008, were included. PBPCs were mobilized with chemotherapy followed by lenograstim at 10 μg/kg/day. Patients received lenograstim at 2000 hours, about half a day before leukapheresis (PM group) before November 2004, and at 0600 hours, 3 h before apheresis (AM group) subsequently. In the AM group, the median number of total collected CD34+ cells/kg was greater over a shorter duration of apheresis, and the median number of collected CD34+ cells/kg at first leukapheresis was larger. Stem cell collection efficacy (ratio of total collected CD34+ cells/kg per number of leukapheresis procedures) was higher, and proportion of patients who yielded an optimum harvest was larger. The statistically significant between-group difference was observed only in patients with high-dose CY chemotherapy for stem cell mobilization in subgroup analysis. The present study showed that G-CSF injection 3 h before apheresis improved the efficacy of autologous stem cell collection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pierre F, Daniele B, Florenece G, Francosis A, Anne S, Veronique LC et al. Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells. Transfusion 2003; 43: 878–884.

    Article  Google Scholar 

  2. Millar BC, Millar JL, Shepherd V, Blackwell P, Porter H, Cunningham D et al. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1998; 22: 469–475.

    Article  CAS  PubMed  Google Scholar 

  3. Fruehauf S, Seggewiss R . It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003; 122: 360–375.

    Article  CAS  PubMed  Google Scholar 

  4. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311–316.

    CAS  PubMed  Google Scholar 

  5. Ergene U, Cagirgan S, Pehlivan M, Yilmaz M, Tombuloglu M . Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). Transfus Apher Sci 2007; 36: 23–29.

    Article  PubMed  Google Scholar 

  6. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H et al. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998; 101: 582–585.

    Article  CAS  PubMed  Google Scholar 

  7. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW et al. Optimizing dose and scheduling of filgrastim (granulocyte colony- stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437–4445.

    CAS  PubMed  Google Scholar 

  8. Kim S, Kim HJ, Park JS, Lee J, Chi HS, Park CJ et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84: 742–747.

    Article  CAS  PubMed  Google Scholar 

  9. Watts MJ, Addison I, Ings SJ, Long SG, Hartley S, Warrington S et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration. Bone Marrow Transplant 1998; 21: 365–368.

    Article  CAS  PubMed  Google Scholar 

  10. Sato S, Kigawa J, Irie T, Itamochi H, Kanamori Y, Kamazawa S et al. Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer. Am J Clin Oncol 2002; 25: 289–290.

    Article  PubMed  Google Scholar 

  11. Assouline S, Sylvester MP, Carriere P, Shustik C, Laneuville P . Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients. Transfusion 2006; 46: 174–179.

    Article  CAS  PubMed  Google Scholar 

  12. Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005; 35: 449–454.

    Article  CAS  PubMed  Google Scholar 

  13. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290.

    Article  CAS  PubMed  Google Scholar 

  14. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001; 19: 4014–4022.

    Article  CAS  PubMed  Google Scholar 

  15. Suh C, Kim S, Kim SH, Kim EK, Lee JL, Park KU et al. Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 2004; 44: 1762–1768.

    Article  PubMed  Google Scholar 

  16. Lee JL, Kim SB, Lee GW, Ryu MH, Kim EK, Kim S et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci 2003; 29: 29–37.

    Article  PubMed  Google Scholar 

  17. Yamaguchi E, Yamato K, Miyata Y . Kinetics of peripheral blood stem cell collection in large-volume leukapheresis for pediatric patients undergoing chemotherapy and adult patients before chemotherapy. J Hematother Stem Cell Res 2000; 9: 565–572.

    Article  CAS  PubMed  Google Scholar 

  18. Lee JL, Kim SB, Lee GW, Ryu MH, Kim EK, Kim S et al. Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest. J Korean Med Sci 2003; 18: 27–35.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Park KU, Kim SH, Suh C, Kim S, Lee SJ, Park JS et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001; 67: 42–47.

    Article  CAS  PubMed  Google Scholar 

  20. Stroncek DF, Matthews CL, Follmann D, Leitman SF . Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. Transfusion 2002; 42: 597–602.

    Article  CAS  PubMed  Google Scholar 

  21. Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander AR . Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004; 44: 104–110.

    Article  PubMed  Google Scholar 

  22. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035–2042.

    Article  CAS  PubMed  Google Scholar 

  23. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282–1284.

    Article  CAS  PubMed  Google Scholar 

  24. Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J et al. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion 2007; 47: 2207–2216.

    Article  PubMed  Google Scholar 

  25. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719–724.

    Article  CAS  PubMed  Google Scholar 

  26. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815–820.

    Article  CAS  PubMed  Google Scholar 

  27. Hoglund M, Smedmyr B, Bengtsson M, Totterman TH, Cour-Chabernaud V, Yver A et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers—a comparative study. Eur J Haematol 1997; 59: 177–183.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    J E Kim, S Kim, D H Lee, S-W Kim, J-S Lee & C Suh

  2. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    C Yoo

Authors
  1. J E Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S-W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J-S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Suh.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J., Yoo, C., Kim, S. et al. Optimal timing of G-CSF administration for effective autologous stem cell collection. Bone Marrow Transplant 46, 806–812 (2011). https://doi.org/10.1038/bmt.2010.194

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.194

Keywords

This article is cited by

Search

Advanced search

Quick links